What Harman Finochem does

Harman Finochem Limited is an India-based pharmaceutical manufacturer founded in 1983 by Mr. Bhupinder Singh Manhas and headquartered in Mumbai, with manufacturing operations in Aurangabad (Site I in Chikalthana and Site II in Shendra) and a planned R&D center in Navi Mumbai. The company manufactures and exports Active Pharmaceutical Ingredients (APIs) — including Metformin HCl (where it is one of the largest global producers), Fenofibrate, Divalproex Sodium, Riboflavin Phosphate Sodium, Glycopyrrolate, and 40+ other APIs across therapeutic categories such as anti-diabetics, antihypertensives, CNS drugs, anesthetics, and bronchodilators. Since 2016 it has operated an integrated Finished Dosage Forms (FDF) facility in Aurangabad producing oral solid dosages, with 2 billion tablets per annum of operational capacity and an additional 8 billion per annum under completion.

The company operates a B2B enterprise sales model exporting APIs, intermediates, and finished dosages to global generic pharmaceutical companies, finished dosage form manufacturers, and contract-manufacturing clients across 75+ countries. Revenue streams include bulk API export, custom contract manufacturing (CMO/CRAMS), and finished dosage form supply. Manufacturing is cGMP-compliant per ICH Q7A guidelines with facilities inspected by USFDA, WHO-GMP, EDQM (Certificate of Suitability for multiple products), TGA, EU GMP, Health Canada, Korean FDA, Japanese MOH, German Health Authorities, and Cofepris. The company is privately held under founder/family control with no disclosed external institutional investors, and is recognized as an Export Trading House by the Ministry of Commerce, Government of India. Its technology stack includes in-house R&D with non-infringing process development, advanced analytical characterization (NMR, IC MS/MS, GCMS, FTIR, XRD), high-pressure reaction capability, fluid bed pelletization (Glatt/Innojet), and full track-and-trace manufacturing systems with COSA 100% tablet inspection. The company is carbon-neutral for Scope 1 and 2 emissions and holds multiple ISO certifications (14001, 37001, 45001, 50001, 27001).

Name

Harman Finochem

Legal name

Harman Finochem Limited

Website

https://harmanfinochem.com

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Harman Finochem is a privately-held Indian pharmaceutical manufacturer founded in 1983 that produces and globally exports 45+ Active Pharmaceutical Ingredients (including Metformin HCl, where it is one of the world's largest producers) and Finished Dosage Forms to generic pharmaceutical companies across 75+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Generic APIs & Intermediates (Active Ingredients) (HLAIABAG), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Controlled Substances / DEA-Scheduled API Manufacturing (HLAGAHAD)

Keywords

• Active pharmaceutical ingredients
• API manufacturing
• Contract manufacturing services
• Finished dosage forms
• Generic drug intermediates

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (API) Manufacturing and Export: Core revenue stream from manufacturing and exporting APIs including Metformin HCl, Fenofibrate, Divalproex Sodium, Riboflavin Phosphate Sodium, Glycopyrrolate/Glycopyrronium bromide. Revenue is generated through direct sales to pharmaceutical companies globally with products sold in bulk quantities under regulatory approvals including CEP, USDMF, and various international regulatory certifications.
2. Contract Manufacturing Organization (CMO) Services: Custom manufacturing of APIs and advanced intermediates for pharmaceutical industry clients. The company offers outsourcing services with focus on enhancing value and competitive advantage throughout the product lifecycle. Revenue generated through project-based contracts for drug development, technology transfer, and commercial production.
3. Finished Dosage Forms Manufacturing: Manufacturing and supply of finished dosage forms including tablets (2 billion tablets per annum capacity with 8 billion additional capacity under completion), offering multiple formats: direct compression, bulk, bottles, and blisters. Revenue from contract manufacturing and co-development partnerships with generic companies.
4. Co-development and New Product Development: Joint development of generic formulations with customers, leveraging core competencies in lifestyle therapies such as anti-diabetics, antihypertensives, CNS acting drugs, gastrointestinals, and anti-gouts. Revenue generated through development fees and subsequent manufacturing agreements.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Harman Finochem manufactures and exports Active Pharmaceutical Ingredients (APIs) including Metformin HCl, Fenofibrate, Divalproex Sodium, Riboflavin Phosphate Sodium, and Glycopyrrolate, supplying 45+ APIs and 10+ WHO Essential Drugs to generic pharmaceutical companies across 75+ countries. The company also operates a Finished Dosage Forms (FDF) manufacturing facility for oral solid dosages (tablets) and offers Contract Manufacturing (CMO) services for APIs, advanced intermediates, CRAMS, and turnkey projects.

Product overview

Harman Finochem is a pharmaceutical company offering a portfolio of over 45 Active Pharmaceutical Ingredients (APIs) including Metformin HCl (its largest product), Fenofibrate, Divalproex Sodium, Riboflavin Phosphate Sodium, Glycopyrrolate, and various anticonvulsants, anesthetics, antihypertensives, and bronchodilators. The company operates integrated Finished Dosage Forms (FDF) manufacturing for oral solid dosages (2 billion tablets/year capacity) and offers Contract Manufacturing (CMO) services for APIs, intermediates, CRAMS, and turnkey projects. A dedicated R&D division develops new products and non-infringing processes, with a new R&D center planned for Navi Mumbai. The product portfolio is organized around APIs (core products), Finished Dosage Forms (formulation), and contract manufacturing services.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) Manufacturing and export of 45+ Active Pharmaceutical Ingredients including 10+ WHO Essential Drugs, supplied in bulk quantities with regulatory documentation (CEP/COS, USDMF) to generic pharmaceutical companies globally.
• Metformin HCl Antidiabetic API offered in API form, direct compression, bulk, bottles, and blisters formats; one of the largest manufactured APIs worldwide.
• Fenofibrate Antilipemic medication API for cholesterol management, supplied with EDQM CEP certification.
• Divalproex Sodium Anticonvulsant medication API manufactured at Site II Shendra, Aurangabad, approved by Cofepris, USFDA, and WHO-GMP.
• Glycopyrrolate (Glycopyrronium bromide) Anticholinergic medication API supplied with EDQM CEP certification for generic pharmaceutical manufacturers.
• Riboflavin Phosphate Sodium Vitamin B2 supplement API with EDQM CEP certification, supplied to pharmaceutical manufacturers globally.
• Finished Dosage Forms (Oral Solid Dosages) Formulation manufacturing facility producing oral solid dosage forms (tablets) with 2 billion tablets per annum capacity (8 billion under completion). Focus on lifestyle therapies including Anti-Diabetics, Antihypertensives, CNS acting drugs, Gastrointestinals, and Anti-gouts. EU GMP and TGA approved.
• Contract Manufacturing (CMO) Services Custom manufacturing of APIs and advanced intermediates for pharmaceutical industry clients, offering outsourcing services on CRAMS and turnkey basis. Focus on enhancing value and competitive advantage throughout the product lifecycle.
• R&D Services Research and Development services including identification and development of new products, non-infringing processes, technology transfer from lab to plant, and process optimization per GMP requirements.

Quantifiable outcome

• Water recycled/reused: 42,109 cubic metres (17.52% of total water consumption)
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Three partnerships are on record, tiered minor.

• Government Hospital, MumbaiminorOthers · 1 January 2021CSR partnership for COVID-19 relief. Donated INR 18.5 million oxygen generator to Government Hospital, Mumbai in 2021 as part of pandemic response efforts.
• Government Hospital, AmravatiminorOthers · 1 January 2021CSR partnership for COVID-19 relief. Donated INR 9.3 million oxygen generator to Government Hospital, Amravati in 2021.
• Government Hospital, AurangabadminorOthers · 1 January 2021CSR partnership for COVID-19 relief. Donated INR 3 million oxygen generator to Government Hospital, Aurangabad in 2021.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Aurobindo Pharma: Large Indian generic API and formulation manufacturer with extensive global regulatory approvals and a comparable product mix spanning cardiovascular, CNS, and anti-diabetic therapies. Directly competes with Harman Finochem in API supply and finished dosage forms to global generic customers.
• MSN Group (MSN Laboratories): Indian-headquartered API and finished dosage manufacturer with strong presence in cardiovascular, anti-diabetic, and CNS categories; similar scale, multi-site India manufacturing, and global regulatory filings. Closest like-for-like comparable to Harman Finochem's API-to-FDF operating model.
• Ipca Laboratories: Indian API and formulations manufacturer with focus on anti-malarials, cardiovascular, and pain management APIs. Comparable in regulatory footprint (USFDA, WHO-GMP), product categories, and export-led B2B model targeting generic pharma companies.
• Morepen Laboratories: Indian API manufacturer globally known as a leading producer of Loratadine and a significant Metformin supplier. Directly comparable given shared focus on bulk API manufacturing for export to generic drug companies across multiple regulatory jurisdictions.
• Granules India: Indian vertically-integrated manufacturer of APIs, pharmaceutical formulation intermediates, and finished dosages with strong global export presence in generics. Comparable API-to-FDF model and similar customer base of generic pharma companies.
• Aarti Drugs: Indian bulk API and intermediate manufacturer focused on therapeutic categories including cardiovascular, anti-diabetic, and CNS-active substances. Comparable mid-scale Indian API exporter with similar target customers in generic pharma worldwide.
• Megafine Pharma: Mumbai-headquartered Indian API manufacturer specializing in cardiovascular, anti-asthmatic, and CNS active substances with USFDA, EU GMP, and WHO-GMP approvals. Closely comparable mid-sized peer with similar therapeutic focus and export-led model.

Broad incumbents

• Divis Laboratories: India-based pure-play API manufacturer (including APIs and intermediates) with global regulatory approvals and contract research/manufacturing services. Larger and more established, with broader API portfolio, but overlapping customer base and similar CDMO business model.
• Laurus Labs: Indian API and formulation manufacturer with global regulatory approvals offering APIs, intermediates, and finished formulations. Overlaps with Harman Finochem in cardiovascular, anti-diabetic, and CNS molecules and the CMO services business.

Emerging players

• Sequent Scientific: Indian API manufacturer serving human and animal health with global regulatory presence. Comparable in targeting generic pharma customers with API supply and contract manufacturing, though smaller scale and different end-market mix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/HarmanFinochem
• Facebookfacebook.com/HarmanFinochemLtd
• LinkedInlinkedin.com/company/1306636

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Harman Finochem